Sirna Therapeutics said last week that it has named Martin Schmieg as senior vice president and CFO.
Schmieg will direct and oversee Sirna’s financial management, accounting activities, and investor and public relations, and will begin at the company on Sept. 20.
Schmieg was most recently senior vice president and CFO of Advanced Bionics, said Sirna. Prior to this, he was president and CEO of advisory firm MSMTC, and executive vice president at Cytometrics. He holds a BS in business administration from La Salle University and is a CPA.
Pestka Biomedical Laboratories said last week that it has appointed Fredric Rhoads has general manager of the company’s research products group.
Rhoads was most recently vice president of sales and marketing at Ambion, said Pestka.
Signet Laboratories said this week that it has named Peggy Taylor as vice president of production and development.
According to the diagnostics and drug developer, Taylor will assume responsibility for Signet’s GMP facility, its production and development team, and its manufacturing and shipping team.
Taylor most recently was with Sequitur, where she established and headed the company’s research program, Signet said. At Sequitur, Taylor served as vice president of research and vice president of collaborative research, according to Signet.
Taylor holds a PhD in cell biology from Harvard University.
Hybridon said this week that its president and CSO, Sudhir Agrawal, has been named CEO.
Agrawal replaces Stephen Seiler, Hybridon said.